Sera Prognostics
Update in progressSERA (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
Sera Prognostics, Inc. is a women’s health company that discovers, develops, and commercializes blood-based biomarker tests and predictive analytics for pregnancy. Its lead test, PreTRM, is a non-invasive blood test for pregnant women with a single fetus during weeks 18–20. The company pursues a pipeline of tests and analytics for pregnancy conditions such as time-to-birth, pregnancy risk, preeclampsia, and fetal growth restriction. Founded in 2008, it is based in Salt Lake City, Utah.
Company score
- Sentiment
- 0.45
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.46
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.17
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.31
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMs. Zhenya Lindgardt M.B.A.
- Founded2008
- Employees71
- Websitewww.sera.com
Identifiers
- ISINUS81749D1072
- FIGIBBG001J19ZJ7
- CUSIP81749D107
- CIK0001534969